oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Metabolomics in atherosclerosis
Department of Public Health and Clinical Medicine, Umeå University and Heart Centre, Umeå, Sweden.ORCID iD: 0000-0002-2957-9904
Department of Public Health and Clinical Medicine, Umeå University and Heart Centre, Umeå, Sweden.
Department of Community Medicine and Rehabilitation, Umeå University, Umeå, Sweden.
Department of Public Health and Clinical Medicine, Umeå University and Heart Centre, Umeå, Sweden.
2015 (English)In: International Journal of Cardiology Metabolic & Endocrine, E-ISSN 2214-7624, Vol. 8, 26-30 p.Article in journal (Refereed) Published
Abstract [en]

It is well established that atherosclerotic cardiovascular disease (ACD) is a leading cause of death in the West. There are several predisposing factors for ACD, which can be divided into two groups: firstly modifiable risk factors, including hypertension, dyslipidaemia, type 2 diabetes mellitus, obesity, smoking and a sedentary lifestyle and secondly the unmodifiable risk factors such as age, gender and heredity. Since single biomarkers are unable to provide sufficient information about the biochemical pathways responsible for the disease, there is a need for a holistic approach technology, e.g. metabolomics, that provide sufficiently detailed information about the metabolic status and assay results will be able to guide food, drug and lifestyle optimisation. Rather than investigating a single pathway, metabolomics deal with the integrated identification of biological and pathological molecular pathways. Mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy are the two most commonly used techniques for metabolite profiling. This detailed review concluded that metabolomics investigations seem to have great potential in identifying small groups of disturbed metabolites which if put together should draw various metabolic routs that lead to the common track pathophysiology. The current evidence in using metabolomics in atherosclerotic cardiovascular disease is also limited and morewell designed studies remain to be established, which might significantly improve the comprehension of atherosclerosis pathophysiology and consequently management.

Place, publisher, year, edition, pages
Elsevier , 2015. Vol. 8, 26-30 p.
Keyword [en]
Atherosclerotic cardiovascular disease, metabolomics, proteomics, lipidomics, atherosclerosis
National Category
Cardiac and Cardiovascular Systems
Research subject
Cardiology; Medicine, cardiovascular disease
Identifiers
URN: urn:nbn:se:oru:diva-57883DOI: 10.1016/j.ijcme.2014.11.004ISI: 000372442100006ScopusID: 2-s2.0-84946416732OAI: oai:DiVA.org:oru-57883DiVA: diva2:1104822
Available from: 2017-06-01 Created: 2017-06-01 Last updated: 2017-06-20

Open Access in DiVA

No full text

Other links

Publisher's full textScopusFulltext

Search in DiVA

By author/editor
Djekic, Demir
In the same journal
International Journal of Cardiology Metabolic & Endocrine
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 5 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf